BR112018075688A2 - anticorpos anti-c5 e métodos de uso - Google Patents
anticorpos anti-c5 e métodos de usoInfo
- Publication number
- BR112018075688A2 BR112018075688A2 BR112018075688-1A BR112018075688A BR112018075688A2 BR 112018075688 A2 BR112018075688 A2 BR 112018075688A2 BR 112018075688 A BR112018075688 A BR 112018075688A BR 112018075688 A2 BR112018075688 A2 BR 112018075688A2
- Authority
- BR
- Brazil
- Prior art keywords
- present
- antibody
- provides
- antibodies
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016120325 | 2016-06-17 | ||
JP2016-120325 | 2016-06-17 | ||
PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018075688A2 true BR112018075688A2 (pt) | 2019-04-02 |
Family
ID=59969459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018075688-1A BR112018075688A2 (pt) | 2016-06-17 | 2017-06-16 | anticorpos anti-c5 e métodos de uso |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP3472316A4 (zh) |
JP (3) | JP6202774B1 (zh) |
KR (2) | KR102226975B1 (zh) |
CN (3) | CN115925922A (zh) |
AU (1) | AU2017285763B2 (zh) |
BR (1) | BR112018075688A2 (zh) |
CA (1) | CA3021956A1 (zh) |
CL (1) | CL2018003573A1 (zh) |
CR (1) | CR20190013A (zh) |
EA (1) | EA201990018A1 (zh) |
IL (2) | IL300611A (zh) |
MX (2) | MX2018015030A (zh) |
MY (1) | MY187848A (zh) |
PE (2) | PE20190394A1 (zh) |
PH (1) | PH12018502354A1 (zh) |
SG (2) | SG10201800265UA (zh) |
TW (4) | TWI610941B (zh) |
UA (1) | UA126561C2 (zh) |
WO (1) | WO2017217524A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
MY195714A (en) | 2008-04-11 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly |
KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
MA45235A (fr) | 2016-06-14 | 2019-04-17 | Regeneron Pharma | Anticorps anti-c5 et leurs utilisations |
KR102226975B1 (ko) * | 2016-06-17 | 2021-03-11 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
CN111278857A (zh) * | 2017-10-04 | 2020-06-12 | 亚力兄制药公司 | 抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用 |
EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
CA3111396A1 (en) * | 2018-09-06 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
WO2020219922A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
CN113563467A (zh) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | 针对人补体蛋白c5的抗体及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0230985Y2 (zh) | 1985-07-08 | 1990-08-21 | ||
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
ATE495618T1 (de) | 2001-06-12 | 2011-01-15 | Ericsson Telefon Ab L M | Synchronisation in einem terrestrischen umts- funkzugriffsnetzwerk (utran) |
ATE360441T1 (de) | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
JP4333939B2 (ja) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | トロリ線の吊架装置 |
DE10253331A1 (de) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Verwendung von trans-Pellitori als Aromastoff |
US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
KR20080069889A (ko) | 2007-03-20 | 2008-07-29 | (주)화도 | 폴리에틸렌 관 |
EP2129681A2 (en) * | 2007-03-22 | 2009-12-09 | Novartis Ag | C5 antigens and uses thereof |
US8420298B2 (en) | 2007-04-11 | 2013-04-16 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
MY195714A (en) * | 2008-04-11 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly |
PE20110225A1 (es) * | 2008-08-05 | 2011-04-05 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 |
KR20100054403A (ko) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | 온라인 공동 작문 장치 및 방법 |
SG10201507722QA (en) * | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
KR20110111007A (ko) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | L/d 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체 |
KR20110122011A (ko) | 2010-05-03 | 2011-11-09 | 황보철종 | 매장 포인트 통합 관리 시스템 및 그 방법 |
WO2014028354A1 (en) * | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
EP2975055A4 (en) * | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
EP3473272A1 (en) * | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
HUE056489T2 (hu) * | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
EP3390442B1 (en) * | 2015-12-18 | 2023-11-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
KR102226975B1 (ko) * | 2016-06-17 | 2021-03-11 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
-
2017
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/ko active IP Right Grant
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/ko active IP Right Grant
- 2017-06-16 TW TW106120143A patent/TWI610941B/zh active
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/zh active Pending
- 2017-06-16 TW TW106141573A patent/TWI789369B/zh active
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/es unknown
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/zh active Pending
- 2017-06-16 TW TW111107923A patent/TWI807666B/zh active
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/zh active Active
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/es unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/ja active Active
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/es unknown
- 2017-06-16 TW TW112120479A patent/TW202337903A/zh unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/pt unknown
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 UA UAA201810992A patent/UA126561C2/uk unknown
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 EA EA201990018A patent/EA201990018A1/ru unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/es unknown
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/ja active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/es unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/es unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018075688A2 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112018009067A8 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112017011235A2 (pt) | anticorpos anti-c5 e métodos de uso | |
AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
CL2019001193A1 (es) | Moléculas de unión a lag-3 y métodos de uso de las mismas. (divisional solicitud 201703132). | |
CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
BR112012023010A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37 | |
BR112015019341A2 (pt) | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal | |
BR112015019343A2 (pt) | Anticorpo anti-her2, composição, método para produção de uma população de anticorpos, células epiteliais das glândulas mamárias, e, mamífero não humano transgênico | |
BR112022000628A2 (pt) | Anticorpos anti-tigit e aplicação dos mesmos | |
BR112018010669A2 (zh) | Anti-PCSK9 antibody and its application | |
AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
BR112015027388A2 (pt) | Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica | |
BR112021022742A2 (pt) | Método de expressão de proteínas de ligação de antígeno no sistema nervoso e uso de um construto de expressão | |
BR112023021587A2 (pt) | Fab anti-tslp com estabilidade melhorada, kit, composição, vetor, célula, método de produção e usos | |
BR112016003441A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, conjugado de droga para anticorpo, métodos para eliminar células que expressam baixos níveis de prlr e de um receptor de citocina classe i e para inibir ou atenuar crescimento de tumor, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023000238-5 PROTOCOLO 870230001345 EM 05/01/2023 16:22. |